2022 Revenues ($USD) : $20,280,056,800.00
2022 Revenues (foreign currencies) : €19,252,000,000
2022 R&D spend : $3,578,399,800.00
2022 Number of Employees : 101,369 (companywide)
Fiscal Year End : 12/31/22
Leader : CEO Bill Anderson (effective June 2023)

Bayer's pharmaceutical division reported strong revenues of €19.3 billion in 2022, with Xarelto, a blood clot-reducing medication, standing out as its top drug, generating roughly €4.5 billion. The company plans to significantly boost its investment in U.S.-based pharmaceutical R&D by earmarking €1 billion (approximately $1 billion) for 2023, aiming to double sales in the country by the end of the decade. Bayer's pharma division concentrates on prescription products, especially for cardiology and women's healthcare. It has a focus on specialty therapeutics in oncology, hematology and ophthalmology. —BB